Title

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor (CAR) T-Cell Therapy

Authoring Organization

Publication Month/Year

November 1, 2021

Last Updated Month/Year

February 8, 2024

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Document Objectives

To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy.

Inclusion Criteria

Male, Female, Adolescent, Adult, Child, Older adult

Health Care Settings

Ambulatory, Hospital, Long term care, Outpatient

Intended Users

Nurse, nurse practitioner, health systems pharmacist, physician, physician assistant

Scope

Management, Prevention

Diseases/Conditions (MeSH)

D007167 - Immunotherapy, D064420 - Drug-Related Side Effects and Adverse Reactions, D000076962 - Receptors, Chimeric Antigen

Keywords

immunotherapy, IRAEs, Cancer immunotherapy, CAR-T, IRAE, Chimeric Antigen Receptor T-Cell

Source Citation

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021 Nov 1:JCO2101992. doi: 10.1200/JCO.21.01992. Epub ahead of print. PMID: 34724386.

Supplemental Methodology Resources

Data Supplement, Evidence Tables, Methodology Supplement

Methodology

Number of Source Documents
63
Literature Search Start Date
March 15, 2020
Literature Search End Date
March 2, 2021